SCHEMBL3525581

SCHEMBL3525581

Clc1cc(Cl)c(Br)c(CBr)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
HSP90AA1 P07900 2/20 0.37
HSD17B10 Q99714 4/20 0.35
HPGD P15428 4/20 0.35
CYP3A4 P08684 4/20 0.35
TSHR P16473 3/20 0.35
RECQL P46063 1/20 0.35
CYP2C9 P11712 4/20 0.32
CYP1A2 P05177 4/20 0.32
HIF1A Q16665 3/20 0.32
CYP2C19 P33261 3/20 0.32
IDO1 P14902 2/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
SLC22A1 O15245 1/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
HSPD1 P10809 1/20 0.32
HSPA5 P11021 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530027 0.79 HSP90AA1 (0.40) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4
SCHEMBL5073560 0.78 ALDH1A1 (0.52) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4
SCHEMBL450499 0.76 ALDH1A1 (0.53) ALDH1A1HSD17B10HPGDCYP3A4TSHR
SCHEMBL1505192 0.74 ALDH1A1 (0.36) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4
SCHEMBL9993152 0.74 HSD17B10 (0.56) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4
SCHEMBL29516784 0.70 HIF1A (0.48) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4
SCHEMBL15129655 0.70 KDM4E (0.33) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4
SCHEMBL18686817 0.69 ALDH1A1 (0.45) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4
SCHEMBL3028712 0.69 ALDH1A1 (0.45) ALDH1A1HSD17B10HPGDCYP3A4TSHR
Bromide SCHEMBL6440480 0.68 HIF1A (0.47) ALDH1A1HSP90AA1HSD17B10HPGDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061767-B1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use SANOFI SA (FR) 2014-12-17 EP disclosed
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
CN-101501005-A Arylaminoaryl-alkyl-substituted imidazolidine-2, 4-diones, processes for their preparation, medicaments comprising these compounds and their use SANOFI AVENTIS (FR) 2009-08-05 CN disclosed
EP-2061767-A1 ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE Sanofi-Aventis (FR) 2009-05-27 EP disclosed
WO-2008017381-A1 ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE SANOFI-AVENTIS (FR) 2008-02-14 WO disclosed
WO-2008017381-A1 ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE SANOFI-AVENTIS (FR) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use GPR119, GIPR, LIPC ALDH1A1 193/4885HSP90AA1 1496/4885HSD17B10 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.